25-07-2018
sprng23 / iStockphoto.com
Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CJEU, Court of Justice of the European Union, SPC, Truvada, Teva, Accord Healthcare, Lupin, Mylan, Gilead, patent, supplementary protection certificate
CJEU hands down SPC guidance in Royalty Pharma
30-04-2020
German patent court publishes reasoning in Gilead SPC dispute
06-11-2018
SPC waiver proposal could discourage innovation, says pharma group
09-08-2018
AG opines on ‘thorny issue’ in Truvada SPC clash
25-04-2018
English High Court refers Truvada SPC case to CJEU
16-01-2017
